Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis

Gastroenterology

Volumn 155, Issue 4, 2018, Pages 1120-1127.e4

  Esteban, Rafael ^a   Pineda, Juan A ^b   Calleja, Jose Luis ^c,d,e   Casado, Marta ^f   Rodríguez, Manuel ^g   Turnes, Juan ^h   Morano Amado, Luis Enrique ⁱ   Morillas, Rosa Maria ^e,j   Forns, Xavier ^k   Pascasio Acevedo, Juan Manuel ^l   Andrade, Raul J ^m   Rivero, Antonio ⁿ   Carrión, José Antonio ^o   Lens, Sabela ^k   Riveiro Barciela, Mar ^e,p   McNabb, Brian ^q   Zhang, Gulan ^q   Camus, Gregory ^q   Stamm, Luisa M ^q   Brainard, Diana M ^q   Subramanian, G Mani ^q   Buti, Maria ^a   more..

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f HOSPITAL TORRECÁRDENAS   (Spain)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^h Instituto de Investigación Sanitaria Galicia Sur   (Spain)

ⁱ Alvaro Cunqueiro University Hospital of Vigo   (Spain)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^k UNIVERSITY OF BARCELONA   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^o UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^p HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^q GILEAD SCIENCES   (United States)

more..

Author keywords

Direct Acting Antiviral Agent; Drug Resistance; Outcome

Indexed keywords

PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; VELPATASVIR; VIRUS RNA; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; SOFOSBUVIR-VELPATASVIR DRUG COMBINATION;

ACCIDENT AT WORK; ADULT; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; INSOMNIA; LIMB INJURY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; NON SMALL CELL LUNG CANCER; OPEN STUDY; PHARYNGITIS; PHARYNGOTONSILLITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; SPAIN; SUSTAINED VIROLOGIC RESPONSE; TONSILLITIS; TRANSIENT ELASTOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; DRUG EFFECT; GENETICS; GENOTYPE; HEPACIVIRUS; MULTICENTER STUDY; PATHOGENICITY; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; CARBAMATES; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; SOFOSBUVIR; SPAIN; SUSTAINED VIROLOGIC RESPONSE; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85054176606     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2018.06.042     Document Type: Article

References (31)

1. Gower, E., Estes, C., Blach, S., et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:1 Suppl (2014), S45–S57.
2. Messina, J.P., Humphreys, I., Flaxman, A., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
3. Bochud, P.Y., Cai, T., Overbeck, K., et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 51 (2009), 655–666.
4. European Association for the Study of the Liver (EASL). EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69 (2018), 461–511.
5. American Association for the Study of Liver Diseases (AASLD), Infectious Disease Society of America (IDSA). HCV guidance: recommendations for testing, managing, and treating hepatitis C. Available at: https://hcvguidelines.org/. Accessed March 15, 2018.
6. Tapper, E.B., Afdhal, N.H., Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepatol 20 (2013), 669–677.
7. Gilead Sciences Inc. EPCLUSA (Sofosbuvir and Velpatasvir) Tablets, for Oral Use. US Prescribing Information. Foster City, CA: Gilead Sciences; revised August 2017.
8. Foster, G.R., Afdhal, N., Roberts, S.K., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
9. Jacobson, I.M., Lawitz, E., Gane, E.J., et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology 153 (2017), 113–122.
10. Younossi, Z.M., Stepanova, M., Sulkowski, M., et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from Astral-2 and -3 clinical trials. Clin Infect Dis 63 (2016), 1042–1048.
11. Younossi, Z.M., Stepanova, M., Jacobson, I.M., et al. Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. Aliment Pharmacol Ther 47 (2018), 259–267.
12. Asselah, T., Bourgeois, S., Pianko, S., et al. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1–6 and compensated cirrhosis or advanced fibrosis. Liver Int 38 (2018), 443–450.
13. Nelson, D.R., Cooper, J.N., Lalezari, J.P., et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61 (2015), 1127–1135.
14. European Association for the Study of the Liver (EASL). EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66 (2017), 1–42.
15. Foster, G.R., Afdhal, N., Roberts, S.K., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 Infection. N Engl J Med 373 (2015), 2608–2617.
16. von Felden, J., Vermehren, J., Ingiliz, P., et al. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. Aliment Pharmacol Ther 47 (2018), 1288–1295.
17. Curry, M.P., O'Leary, J.G., Bzowej, N., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
18. Pianko, S., Flamm, S.L., Shiffman, M.L., et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med 163 (2015), 809–817.
19. Wei, L., Omata, M., Lim, Y.-S., et al. Prevalence of Pretreatment NS5A and NS5B NI-Resistance Associated Substitutions in HCV-Infected Patients Enrolled in Clinical Trials in Asia. Hepatol Int, 11(Suppl 1), 2017 S189 [LB009].
20. Cento, V., Sorbo, M.C., Bertoli, A., et al. Natural NS3, NS5A, and NS5B HCV resistance is common in real practice, differently associated to HCV genotypes and response to HS5A inhibitors. Hepatology, 63(Suppl 1), 2016 368A [Abstract 744].
21. Gilead Sciences Ireland UC. Epclusa 400 mg/100 mg Film Coated Tablets. Summary of Product Characteristics (SmPC). Foster City, CA: Gilead Sciences; revised May 2017.
22. Hoffmann-Roche Inc. COPEGUS (Ribavirin) Tablets, for Oral Use. US Prescribing Information. Revised August 2015.
23. Roche Products Limited. Copegus (Ribavirin) 400 mg Film-Coated Tablets for Oral Use. Summary of Product Characteristics. Revised February, 2015.
24. Leroy, V., Angus, P., Bronowicki, J.P., et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 63 (2016), 1430–1441.
25. Jacobson, I.M., Lawitz, E., Gane, E.J., et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology 153 (2017), 113–122.
26. Feld, J.J., Jacobson, I.M., Sulkowski, M.S., et al. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int 37 (2017), 5–18.
27. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Available at: http://apps.who.int/iris/bitstream/10665/206453/1/WHO_HIV_2016.04_eng.pdf?ua=1. Published May 2016. Accessed May 17, 2018.
28. Tyrfingsson, T., Runarsdottir, V., Hansdottir, I., et al. Marked reduction in the prevalence of hepatitis C viremia among people who inject drugs during 2nd year of the Treatment as Prevention (TraP HepC) program in Iceland. J Hepatol, 68(Suppl 1), 2018 S52 [PS-095].
29. Mangia, A., Piazzolla, V., Losappio, R., et al. High SVR rates in patients with and without cirrhosis treated in real life with sofosbuvir/velpatasvir (SOF/VEL) combination for 12 weeks without ribavirin (RBV). Presented at the 53rd Annual Meeting of the European Association for the Study of the Liver April 11–15, 2018, Paris, France. J Hepatol, 68(Suppl 1), 2018 S273–S274 [THU-323].
30. Mangia, A., Cenderrello, G., Copetti, M., et al. The evolution of treatment for HCV genotype 3 (GT3) infected patients with advanced fibrosis/cirrhosis over time. Presented at the 53rd Annual Meeting of the European Association for the Study of the Liver April 11–15, 2018, Paris, France. J Hepatol, 68(Suppl 1), 2018 S105 [THU-324].
31. Bourliere, M., Gordon, S.C., Flamm, S.L., et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 376 (2017), 2134–2146.